The company recently filed its first provisional patent application for use of anti-adhesion molecule therapies to treat FIV infections, and has identified three candidate antibodies that are likely to have potential for activity in the feline system.
FIV has been reported to cause an AIDS-like syndrome in the domestic cat and is a distant relative of HIV, the cause of AIDS in humans, the company said.
The company said that currently there is no satisfactory therapeutic treatment for FIV on the market.